Journal article
Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial
G Tapia Rico, T Price, N Tebbutt, J Hardingham, C Lee, L Buizen, K Wilson, V Gebski, A Townsend
Clinical Colorectal Cancer | CIG MEDIA GROUP, LP | Published : 2019
Abstract
For metastatic colorectal cancer, previous reports have described differences in biology and outcomes, including response to biological therapies, based on the sidedness (left vs. right) of the primary lesion. We explored the molecular markers from the AGITG MAX trial and found that right-sided cancer patients had poorer outcomes. We also found that the effectiveness of bevacizumab was independent of the site of the primary lesion.
Grants
Funding Acknowledgements
Funding for the molecular testing was received from the Cancer Council South Australian. Additional untied funding was provided by Roche Australia. Statistical analysis was provided by NHMRC CTC.